Bio-Thera Reports the US FDA’s Approval of Avzivi (Biosimilar, Avastin)

Share this

Bio-Thera Reports the US FDA’s Approval of Avzivi (Biosimilar, Avastin)


  • The FDA granted approval to Avzivi (BAT1706) based on a thorough analysis of analytical, non-clinical, & clinical data and the comparative studies b/w Avzivi and Avastin which confirmed biosimilarity by assessing structural, physicochemical, and biological properties
  • The randomized, double-blind, three-arm parallel P-III trial investigated Avzivi vs Avastin for their efficacy, safety, and immunogenicity in treating advanced non-squamous NSCLC
  • Bio-Thera will develop and manufacture Avzivi, while Sandoz has global (incl. US) commercialization rights as per a license and commercialization agreement initiated in Sep 2021

Ref: Bio-Thera Solutions | Image: Bio-Thera Solutions

Related News:- Bio-Thera Reported Positive Results of BAT2206 (biosimilar ustekinumab) in P-III Study for Patients with Plaque Psoriasis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions